Logo

Biogen's Spinraza (nusinersen) Receives NMPA (CFDA) Approval for Spinal Muscular Atrophy (SMA) Aged 6wks.

Share this

Biogen's Spinraza (nusinersen) Receives NMPA (CFDA) Approval for Spinal Muscular Atrophy (SMA) Aged 6wks.

Shots:

  • The approval is based on P-II NURTURE study results assessing Spinraza in 300 infant patients who were genetically diagnosed with SMA and had not experienced any symptoms by the time of first dose aged 6 wks.
  • The study resulted in early treatment allow 100% progressive gains in motor function- reduction in mortality in infants- 88% able to walk and safe and efficacious profile
  • Spinraza (nusinersen) is antisense oligonucleotide (ASO) developed using Ionis’ antisense technology delivered using intrathecal injection directly to CSF targeted to treat SMA and is approved in 40 countries for SMA 

Ref: Biogen | Image: INA Pharmacy

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions